Trials / Withdrawn
WithdrawnNCT01164540
Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,000 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep vein thrombosis or pulmonary embolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin (AZD4522) | Oral dose (od) 20 mg |
| DRUG | Placebo | Oral dose (od) |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2010-07-16
- Last updated
- 2010-12-10
Source: ClinicalTrials.gov record NCT01164540. Inclusion in this directory is not an endorsement.